Avere Therapeutics Debuts on Nasdaq Backed by Ex-Akero Leaders Behind Novo Nordisk Acquisition
The company just went public via a $320M reverse merger with NextCure and is advancing a promising once-weekly oral IL-23 inhibitor for psoriasis and ulcerative colitis.